Tocilizumab Dose Optimization in Rheumatoid Arthritis
Where in Netherlands
- Alkmaar · Noordwest Ziekenhuisgroep StichtingTaking people
- Amsterdam · Amsterdam UMC StichtingTaking people
- Amsterdam · Reade revalidatie & reumatologie centrum te AmsterdamTaking people
- Rotterdam · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Taking people
- Rotterdam · Maasstad Ziekenhuis StichtingTaking people
- Ubbergen · Sint Maartenskliniek StichtingTaking people
The registry text, word for word
Concentration guided dose reduction versus standard dosing in tocilizumab treated heumatoid arthritis patients:a randomised, international, multicenter, non-inferiority trial
The main objective is to investigate the difference in mean time weighted Disease Activity Score in 28 joints, including erythrocyte sedimentation rate (DAS28-ESR) in patients with RA with serum trough concentrations higher than 15 mg/L who are randomly assigned to continuation of the standard dose or to increase dosing interval to every two weeks.
Inclusion: Rheumatoid arthritis according to the ACR 1987 or 2010 criteria; Current use of subcutaneous tocilizumab 162 mg weekly , for at least the last 6 months; The treating rheumatologist is convinced of the benefit of tocilizumab continuation; No changes in the treatment with glucocorticoids and DMARDs such as methotrexate in the past three months; Written informed consent.
Exclusion: A scheduled surgery in the next 52 weeks or other pre-planned reasons for treatment discontinuation.